Spironolactone prevents hyperkaleamia in transgender teens

According to data, published in the Journal of the Endocrine Society, only 2.2% of transgender adolescents treated with spironolactone developed hyperkalemia after starting initiation therapy.

Healio

Subscribe to our email alerts